Evercore ISI analyst Ross Muken said Danaher (DHR) acquired one of the complex's best assets at a highly attractive price with its deal to buy GE Biopharma from GE (GE). After meeting with Danaher management to discuss the deal, Muken said they were "very excited" and he believes his estimates are likely conservative post the meeting. The analyst, who sees several years' worth of highly visible low-double digit EPS growth ahead for Danaher, called the stock, along with Thermo Fisher (TMO), the "must-own equities within the Life Science universe." Muken has an Outperform rating and $130 price target on Danaher shares.

Citi raised the firm's price target on GE Aerospace to $186 from $120.43 and keeps a Buy rating on the shares. The company's' Q1 was better than expected and it modestly increased its full-year EBIT outlook, the analyst tells investors in a research note. The firm says commercial aftermarket demand remains robust.

Barclays analyst Luke Sergott raised the firm's price target on Thermo Fisher to $615 from $590 and keeps an Equal Weight rating on the shares. The company reported a beat across the board, says the analyst, who sees the business stabilizing.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

BofA analyst Ronald Epstein raised the firm's price target on GE Aerospace to $180 from $165 and keeps a Buy rating on the shares. GE boasts a unique portfolio with exposure across aircraft manufacturers, aircraft classes, legacy/new/nextgen platforms, and aftermarket/OE customers, says the firm, which believes GE is "strongly positioned to benefit from secular commercial aero growth."

Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.

Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.